Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters - PubMed (original) (raw)
Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters
C Lanvers-Kaminsky et al. Pediatr Blood Cancer. 2006 Aug.
Abstract
Background: To overcome the ototoxicity of cisplatin, single bolus infusions were replaced by repeated prolonged infusions of lower doses or by continuous infusions at still lower infusion rates. However, considering ototoxicity little is, in fact, known about the tolerance of repeated prolonged or continuous infusion in children.
Procedure: Auditory function was monitored along with plasma concentrations of free and total platinum (Pt), and with standard serum parameters (sodium, potassium, calcium, magnesium, phosphate, chloride, and creatinine) in 24 children receiving cisplatin by continuous infusion for the treatment of neuroblastoma and osteosarcoma or by repeated 1 or 6 hr infusions for the treatment of germ cell tumors.
Results: Hearing deteriorated in 10/15 osteosarcoma patients, 2/3 neuroblastoma patients, and 1/6 patients with germ cell tumors. Ototoxicity occurred after cumulative doses between 120 and 360 mg/m(2) cisplatin. In osteosarcoma patients, ototoxicity was associated with a comparatively higher mean plasma concentration of free Pt. However, Pt plasma concentrations did not discriminate between patients with or without ototoxicity. In patients experiencing ototoxicity serum creatinine increased by 45% compared to pre-treatment levels (mean). Serum creatinine increased by 26% in patients without ototoxicity (P < 0.05, Mann-Whitney Rank sum test). Despite standardized hydration, discrete but significant changes of potassium, sodium, magnesium, and phosphate were observed during and/or after cisplatin infusion, which, however, did not discriminate between patients with and without ototoxicity.
Conclusions: While continuous cisplatin infusions are less nephrotoxic than repeated prolonged infusions, we observed considerable ototoxicity in patients treated with continuous cisplatin infusions, which necessitates further evaluations on the tolerance of continuous cisplatin infusions in children.
Similar articles
- Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors.
Gupta AA, Capra M, Papaioannou V, Hall G, Maze R, Dix D, Weitzman S. Gupta AA, et al. J Pediatr Hematol Oncol. 2006 Feb;28(2):91-4. doi: 10.1097/01.mph.0000199586.98926.8e. J Pediatr Hematol Oncol. 2006. PMID: 16462581 - Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss.
Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N, Hartmann O. Bertolini P, et al. J Pediatr Hematol Oncol. 2004 Oct;26(10):649-55. J Pediatr Hematol Oncol. 2004. PMID: 15454836 - High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A, Hansson J, Ehrsson H, Eksborg S, Wallin I, Wagenius G, Laurell G. Ekborn A, et al. Laryngoscope. 2004 Sep;114(9):1660-7. doi: 10.1097/00005537-200409000-00030. Laryngoscope. 2004. PMID: 15475801 - Recovery from cisplatin-induced ototoxicity: a case report and review.
Truong MT, Winzelberg J, Chang KW. Truong MT, et al. Int J Pediatr Otorhinolaryngol. 2007 Oct;71(10):1631-8. doi: 10.1016/j.ijporl.2007.06.021. Epub 2007 Aug 15. Int J Pediatr Otorhinolaryngol. 2007. PMID: 17706797 Review. - Mechanisms of cisplatin ototoxicity and progress in otoprotection.
Rybak LP. Rybak LP. Curr Opin Otolaryngol Head Neck Surg. 2007 Oct;15(5):364-9. doi: 10.1097/MOO.0b013e3282eee452. Curr Opin Otolaryngol Head Neck Surg. 2007. PMID: 17823555 Review.
Cited by
- N-acetylcysteine chemoprotection without decreased cisplatin antitumor efficacy in pediatric tumor models.
Muldoon LL, Wu YJ, Pagel MA, Neuwelt EA. Muldoon LL, et al. J Neurooncol. 2015 Feb;121(3):433-40. doi: 10.1007/s11060-014-1657-1. Epub 2014 Nov 21. J Neurooncol. 2015. PMID: 25411097 Free PMC article. - The identification of dual protective agents against cisplatin-induced oto- and nephrotoxicity using the zebrafish model.
Wertman JN, Melong N, Stoyek MR, Piccolo O, Langley S, Orr B, Steele SL, Razaghi B, Berman JN. Wertman JN, et al. Elife. 2020 Jul 28;9:e56235. doi: 10.7554/eLife.56235. Elife. 2020. PMID: 32720645 Free PMC article. - Atypical teratoid rhabdoid tumor: improved long-term survival with an intensive multimodal therapy and delayed radiotherapy. The Medical University of Vienna Experience 1992-2012.
Slavc I, Chocholous M, Leiss U, Haberler C, Peyrl A, Azizi AA, Dieckmann K, Woehrer A, Peters C, Widhalm G, Dorfer C, Czech T. Slavc I, et al. Cancer Med. 2014 Feb;3(1):91-100. doi: 10.1002/cam4.161. Epub 2013 Dec 11. Cancer Med. 2014. PMID: 24402832 Free PMC article. - Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW, van den Berg H, van Dalen EC. van As JW, et al. Cochrane Database Syst Rev. 2020 Jan 21;1(1):CD010885. doi: 10.1002/14651858.CD010885.pub5. Cochrane Database Syst Rev. 2020. PMID: 31961948 Free PMC article. - Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW, van den Berg H, van Dalen EC. van As JW, et al. Cochrane Database Syst Rev. 2018 Jul 5;7(7):CD010885. doi: 10.1002/14651858.CD010885.pub4. Cochrane Database Syst Rev. 2018. PMID: 29975402 Free PMC article. Updated.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources